6) Enabling Science
Abstract
Protection of the Warfighter against Chemical Warfare Agents (CWAs) to maintain force lethality is the ultimate goal of the Enabling Sciences portfolio. The portfolio leverages innovative approaches and emerging technologies to support modernization of chemical medical countermeasure (cMCM) pipeline. The portfolio is designed to develop and deploy cMCMs more rapidly to the warfighter. Portfolio elements include: 1) development of Artificial Intelligence/Machine Learning (AI/ML) tools to more efficiently identify cMCMs and assess their safety and efficacy for regulatory submission; 2) AI/ultra-high throughput screening-based sampling of large chemical spaces with the aim of providing broad spectrum cMCMs with improved efficacy and selectivity, minimal toxicity, and decreased expense and fielding times to the warfighter; 3) development of technologies to deliver MCMs across the blood brain barrier (BBB) into the brain; 4) maturation of cMCMs with innovative mechanisms of actions; and 5) development of well characterized or FDA qualified animal models, as needed, to support cMCM discovery and development under the FDA animal rule.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2023
- Source ID
- d06bd8d56e0e860f4ac50eab8a5b9953